THAT.LSE Thalia Therapeutics Plc

Healthcare Biotechnology London Exchange
0.0060 GBX
Close of Nov 3, 2026
0.4000 0.9500
Market cap
GBX 10.7M
P/E
-
P/B
4.15x
ROE
-122.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is THAT.LSE undervalued?

Graham number

The Graham number of Thalia Therapeutics Plc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Thalia Therapeutics Plc fundamental analysis

No fundamental analysis for Thalia Therapeutics Plc yet.

Thalia Therapeutics Plc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Thalia Therapeutics Plc

Thalia Therapeutics Plc, a biotechnology company, develops and delivers RNA-based therapeutics and technologies in oncology and cardiovascular disease in the United Kingdom. The company develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines. It also develops Nuvec, a pipeline of RNA therapeutics; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also en…

Full company profile